Form 4 for JAZZ Jazz Pharmaceuticals plc
Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-26 · accession 0001989533-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | 2026-02-26 | JAZZ | Henderson Mary Elizabeth | SVP, Technical Ops | A - Grant | $0.00 | +4,447 | 34.1K | +15% | $0 | |
| 2026-03-02 | 2026-02-26 | JAZZ | Henderson Mary Elizabeth | SVP, Technical Ops | S - Sale | $194.49 | -5,343 | 28.7K | -16% | -$1.04M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-02-26 | A | A | 4,447 | $0.00 | 34,071 | D | — | — | |
| 2 | Common | Ordinary Shares | 2026-02-26 | S | D | 5,343 | $194.49 | 28,728 | D | — | — | (F3) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $194.1900 to $194.5000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |